Next Article in Journal
Evidence to Support the Collaboration of SP1, MYC, and HIF1A and Their Association with microRNAs
Next Article in Special Issue
Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens
Previous Article in Journal
Comparative Analysis of Two Soybean Cultivars Revealed Tolerance Mechanisms Underlying Soybean Adaptation to Flooding
Previous Article in Special Issue
Targeting PGK1: A New Frontier in Breast Cancer Therapy Under Hypoxic Conditions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
CIMB
Volume 46
Issue 11
10.3390/cimb46110740
cimb-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Complementary Treatment of Breast Cancer Cells with Different Metastatic Potential with Iscador Qu in the Presence of Clinically Approved Anticancer Drugs

by
Ivan Iliev
1,
Iana Tsoneva
2,
Aleksandrina Nesheva
2,
Galya Staneva
2,*,
Bozhil Robev
3,
Albena Momchilova
2 and
Biliana Nikolova
2,*
1
Institute of Experimental Morphology, Pathology and Anthropology with Museum, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bl. 25, 1113 Sofia, Bulgaria
2
Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Bl. 21, 1113 Sofia, Bulgaria
3
Department of Medical Oncology, University Hospital “Sv. Ivan Rilski”, 15 Acad. Ivan Geshov Blvd, 1431 Sofia, Bulgaria
*
Authors to whom correspondence should be addressed.
Curr. Issues Mol. Biol. 2024, 46(11), 12457-12480; https://doi.org/10.3390/cimb46110740
Submission received: 12 August 2024 / Revised: 28 October 2024 / Accepted: 3 November 2024 / Published: 5 November 2024
(This article belongs to the Special Issue Advances in Pharmacotherapeutic Strategies to Prevent Tumor Development, Progression and Treatment Resistance)
Browse Figures
Versions Notes

Abstract

European mistletoe extract (Iscador Qu) has been studied for decades, but it has not ceased to arouse scientific interest. The purpose was to investigate the impact of Iscador Qu on the antiproliferative potential of 11 standard chemotherapeutic agents on two breast cancer cell lines: MCF-7 low-metastatic and MDA-MB-231 high-metastatic and control cell lines (MCF-10A). MTT-dye reduction assay, FACS analysis, and PI staining were utilized. The most promising combinations acting against the MDA-MB-231 cell line were observed upon the simultaneous application of Iscador Qu (80 µg/mL) and Docetaxel, with 4-fold reduction in IC50. An antagonistic effect was found under treatment with Cisplatin and Iscador Qu (1.5-fold increase in IC50). The response of the low-metastatic breast cancer cell line MCF-7 to the tested combinations was different compared to the high-metastatic one. The most pronounced cytotoxic effect was found for the combination of Oxaliplatin and Iscador Qu (20 µg/mL) (5.2-fold IC50 reduction). An antagonistic effect for MCF-7 line was also observed when combinations with Olaparib and Tamoxifen were applied. This in vitro study offers new combinations between Iscador Qu and standard chemotherapeutic agents that hold great promise in establishing breast cancer therapeutic protocols compared to traditional monotherapies.
Keywords: Iscador Qu; antiproliferative activity; cytotoxicity; breast cancer cells; anticancer drugs; complementary treatment Iscador Qu; antiproliferative activity; cytotoxicity; breast cancer cells; anticancer drugs; complementary treatment

Share and Cite

MDPI and ACS Style

Iliev, I.; Tsoneva, I.; Nesheva, A.; Staneva, G.; Robev, B.; Momchilova, A.; Nikolova, B. Complementary Treatment of Breast Cancer Cells with Different Metastatic Potential with Iscador Qu in the Presence of Clinically Approved Anticancer Drugs. Curr. Issues Mol. Biol. 2024, 46, 12457-12480. https://doi.org/10.3390/cimb46110740

AMA Style

Iliev I, Tsoneva I, Nesheva A, Staneva G, Robev B, Momchilova A, Nikolova B. Complementary Treatment of Breast Cancer Cells with Different Metastatic Potential with Iscador Qu in the Presence of Clinically Approved Anticancer Drugs. Current Issues in Molecular Biology. 2024; 46(11):12457-12480. https://doi.org/10.3390/cimb46110740

Chicago/Turabian Style

Iliev, Ivan, Iana Tsoneva, Aleksandrina Nesheva, Galya Staneva, Bozhil Robev, Albena Momchilova, and Biliana Nikolova. 2024. "Complementary Treatment of Breast Cancer Cells with Different Metastatic Potential with Iscador Qu in the Presence of Clinically Approved Anticancer Drugs" Current Issues in Molecular Biology 46, no. 11: 12457-12480. https://doi.org/10.3390/cimb46110740

APA Style

Iliev, I., Tsoneva, I., Nesheva, A., Staneva, G., Robev, B., Momchilova, A., & Nikolova, B. (2024). Complementary Treatment of Breast Cancer Cells with Different Metastatic Potential with Iscador Qu in the Presence of Clinically Approved Anticancer Drugs. Current Issues in Molecular Biology, 46(11), 12457-12480. https://doi.org/10.3390/cimb46110740

Article Metrics

Back to TopTop